SequelSEC

BICYCLE THERAPEUTICS PLC BCYC

Pharmaceutical Preparations · CIK 0001761612 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$83.53M
Fiscal year ended 2026-09-30
Operating income
-$158.23M
Fiscal year ended 2026-09-30
Free cash flow
-$177.04M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$266.67MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue3.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio11.98x84th
Revenue YoY growth105.8%84th
SBC / revenue54.4%63th
FCF margin-347.2%38th
CapEx / revenue3.2%60th
R&D / revenue331.0%58th
Net margin-301.7%44th
Operating margin-340.4%45th

BICYCLE THERAPEUTICS PLC (BCYC) reported revenue of $83.53M and net income of -$141.79M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BICYCLE THERAPEUTICS PLC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BICYCLE THERAPEUTICS PLC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Revenue$83.53M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$158.23M
Net income-$141.79M
Research & development$175.25M
Weighted-average diluted sharesUnavailable
Pretax income-$139.09M
Income tax expense$2.70M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$66.50M
Selling & marketingUnavailable

Balance

BICYCLE THERAPEUTICS PLC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$469.93M
Total assets$567.18M
Current assets$537.56M
Total liabilities$61.90M
Current liabilities$44.46M
Total equity incl. NCI$505.28M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$9.59M

Cash flow

BICYCLE THERAPEUTICS PLC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow-$175.18M
Capital expenditures$1.86M
Investing cash flow-$1.86M
Financing cash flow-$150.00K
Net change in cash-$178.89M
Stock-based compensation$30.40M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$4.63M

Derived

BICYCLE THERAPEUTICS PLC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flow-$177.04M
Gross marginUnavailable
Operating margin-189.4%
FCF margin-211.9%
SBC / revenue36.4%
Current ratio12.09x
Revenue YoY growth194.7%
Net margin-169.8%
R&D / revenue209.8%
CapEx / revenue2.2%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BCYC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.